EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Comparison of one‐stage and chromogenic factor VIII assays to tailor the dose of recombinant factor VIII‐Fc fusion protein (rFVIIIFc, efmoroctocog alfa) in adult patients with haemophilia A: Single‐centre, real‐world experience of surgery

Stéphanie Désage iD, Christophe Nougier, Sandrine Meunier iD, Valérie Chamouard, Emilie Jousselme, Yesim Dargaud, Anne Lienhart

Haemophilia · 2024

DOI: 10.1111/hae.14929 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Haemophilia, 2024. Verfasst von Stéphanie Désage und 6 weiteren Autor:innen. Beteiligte Einrichtung: Unité d'Hémostase Clinique, Hôpital Cardiologique Louis Pradel, Hospices Civils de Lyon, Lyon, France. Hauptthemen laut MEDLINE: Factor VIII, Hemophilia A, Immunoglobulin Fc Fragments. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: No funding were received for this study..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Efmoroctocog alfa (rFVIIIFc) is an extended half‐life FVIII used notably in surgery for patients with haemophilia A. More information is needed of its usage in real‐life.

Methods

Adult patients with HA followed at the Lyon Comprehensive Hemophilia Care Center who underwent a surgery with rFVIIIFc were included in this retrospective analysis. The pharmacokinetics of rFVIIIFc was assessed by plasma factor VIII clotting activity (FVIII:C) using both one‐stage (OSA) and chromogenic substrate (CSA) assays.

Results

A total of 39 major and 31 minor surgeries were performed in 49 patients treated with rFVIIIFc. The median dose of rFVIIIFc infused before major and minor surgeries respectively was 67.5 ((interquartile range [IQR] 52.6‐76.9) and 48.0 (38.5‐51.8) IU/kg. For major surgeries, during the first postoperative week, the median residual FVIII:C was 78 (64.5‐101.5) IU/dL with OSA and 99 (71‐118) IU/dL with CSA ( p < .0001). After surgery, rFVIIIFc doses were adjusted according to CSA results. This led to a significant decrease of rFVIIIFc consumption compared to what would have been proposed according to the OSA assay, without unusual bleeding or appearance of inhibitor. Considering the high price of the molecule, this was also associated with a significant cost reduction.

Conclusion

Dose adjustment of rFVIIIFc according to FVIII: C measured by CSA is effective, safe and well tolerated in patients with haemophilia A undergoing invasive surgery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Factor VIIIHemophilia AImmunoglobulin Fc FragmentsAdultHumansRetrospective StudiesRecombinant Fusion ProteinsRecombinant ProteinsHalf-Life

Stichwörter der Autor:innen

Efmoroctocog alfachromogenic factor VIII clotting activityhaemophilia Asurgery

Substanzen

factor VIII-Fc fusion proteinFactor VIIIRecombinant Fusion ProteinsRecombinant ProteinsImmunoglobulin Fc Fragments

Autor:innen und Institutionen

  • Unité d'Hémostase Clinique, Hôpital Cardiologique Louis Pradel, Hospices Civils de Lyon, Lyon, France.
  • Laboratoire d'Hémostase, Centre de Biologie et de Pathologie Est, Hospices Civils de Lyon, Lyon, France.
  • UR4609 Hémostase et Thrombose, Faculté de médecine RTH Laënnec, Université Claude Bernard Lyon 1, Lyon, France.

ORCID-Profile: Stéphanie Désage, Sandrine Meunier

Förderung

  • No funding were received for this study.

Zitieren

APA

Désage, S., Nougier, C., Meunier, S., Chamouard, V., Jousselme, E., Dargaud, Y., & Lienhart, A. (2024). Comparison of one‐stage and chromogenic factor VIII assays to tailor the dose of recombinant factor VIII‐Fc fusion protein (rFVIIIFc, efmoroctocog alfa) in adult patients with haemophilia A: Single‐centre, real‐world experience of surgery. Haemophilia. https://doi.org/10.1111/hae.14929

Vancouver

Désage S, Nougier C, Meunier S, Chamouard V, Jousselme E, Dargaud Y, et al. Comparison of one‐stage and chromogenic factor VIII assays to tailor the dose of recombinant factor VIII‐Fc fusion protein (rFVIIIFc, efmoroctocog alfa) in adult patients with haemophilia A: Single‐centre, real‐world experience of surgery. Haemophilia. 2024. doi:10.1111/hae.14929

BibTeX
@article{Dsage2024,
  author = {Désage, Stéphanie and Nougier, Christophe and Meunier, Sandrine and Chamouard, Valérie and Jousselme, Emilie and Dargaud, Yesim and Lienhart, Anne},
  title = {Comparison of one‐stage and chromogenic factor VIII assays to tailor the dose of recombinant factor VIII‐Fc fusion protein (rFVIIIFc, efmoroctocog alfa) in adult patients with haemophilia A: Single‐centre, real‐world experience of surgery},
  journal = {Haemophilia},
  year = {2024},
  doi = {10.1111/hae.14929}
}
Kostenlos starten →